{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Status:
Investigational
Source:
INN:phenyracillin [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Phenyracillin is the 2,5-diphenylpiperazine salt of benzylpenicillin. It is antibiotic from Pencillium spp. and also other fungal spp. Shows activity against gram-positive bacteria. Phenyracillin was well tolerated.
Class (Stereo):
CHEMICAL (RACEMIC)
Butocrolol amino alcohol derivative with β-adrenolytic, antiarrhythmic, and local anesthetic properties having sympatholytic and antiarrhythmic effects comparable to those of propranolol, but with lower local anesthetic effects.
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Doxaminol is a recently developed beta-sympathomimetic agent, which has shown promising positive inotropic activity in experimental animal models. It is a dibenzoxepine derivative. In normal volunteers, doxaminol exhibits effects on noninvasive cardiological indices similar to those observed after cardiac glycosides. After single-dose application of doxaminol in cases of congestive heart failure, cardiac output and stroke volume increased, heart rate increased slightly, pulmonary and systemic arterial pressure remained constant, and peripheral vascular resistance decreased. No arrhythmias appeared, but one patient suffered an attack of angina.
Status:
Investigational
Source:
NCT04020224: Not Applicable Interventional Withdrawn Safety Issues
(2024)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Amustaline (S-303) is a quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs). When S-303 is added to red blood cells, the compound rapidly passes through membranes, including those of cells and viral envelopes, due to its amphipathic character, and intercalates into helical regions of the nucleic acids of pathogens and white blood cells. TERCEPTTMBlood System usingamustaline (S-303) and glutathione (GSH) was able to inactivate high levels of DENV and ZIKV in RBCs. S-303 system has been shown to effectively inactivate a broad spectrum of pathogens, while maintaining RBC quality.
Class (Stereo):
CHEMICAL (RACEMIC)
Metiprenaline was developed as a bronchodilator. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (UNKNOWN)
Lucimycin (lucensomycin or etruscomycin) is a polyene antibiotic with antimycotic activity. Originally it was isolated from Streptomyces lucensis n. sp.
Status:
Investigational
Source:
INN:dimecolonium iodide [INN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Dimecolonium is the N-cholinolytic drug. It is the ganglion-blocking agent. The functional activity in some ganglioid neurones increases after administration of various doses of dimecolin during the blockade and after its termination.
Class (Stereo):
CHEMICAL (ABSOLUTE)
GALARUBICIN (DA-125) is an anthracycline derivative with anticancer activity, containing fluorine. The mechanism of action of this drug lies in inhibition of nucleic acid synthesis through intercalation with DNA. Because the structure and DNA-intercalating properties of DA-125 are similar to adriamycin, the cytotoxic effects of the two anthracyclines probably have similar biochemical mechanisms. Preclinical studies suggest that it may have greater activity and less cardiac toxicity than adriamycin. In a rodent study, administration of D-125 in higher dose levels (25 to 50 mg/kg) has been shown to result in testicular damage.
Status:
Investigational
Source:
NCT01097018: Phase 3 Interventional Completed Colorectal Cancer
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Perifosine is an Akt inhibitor, which targets the pleckstrin homology domain of Akt, thereby preventing its translocation to the plasma membrane. Perifosine exerts Akt-dependent and Akt-independent effects, and although many preclinical studies have documented Akt inhibition by perifosine, clinical validation of these findings is lacking. Perifosine is in phase II and III clinical trials for the treatment of neuroblastoma, glioblastoma multiforme and other solid tumors.
Status:
Investigational
Source:
NCT00048022: Phase 2 Interventional Completed Asthma
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Valategrast (R-411) is a dual-acting α4/β1 - α4/β7 integrin antagonist which underwent clinical development with Roche for the treatment of multiple sclerosis (MS) and asthma. Phase I and II studies have been
conducted. It had shown good efficacy in animal disease models. Following oral administration, R-411 was rapidly
and completely biotransformed into its active metabolite, RO-0270608, most of which was eliminated by biliary excretion. R-411 had shown acceptable pharmacokinetics and
good safety in healthy volunteers. R-411 inhibited eosinophil and T H 2 cell excitation and survival, and inhibited eosinophil migration from blood to pulmonary tissues. The idea of combining R-411 with montelukast (leukotriene antagonist) in the pharmaceutical dosage
forms, therefore, provided a therapeutic treatment that had the combined effect of reducing circulating eosinophil counts
and reducing eosinophil egress into pulmonary tissues, thereby providing an early onset of bronchodilation as well as sustained anti-inflammatory effects. Valategrast had been in phase II clinical trials by Roche for the treatment of asthma and in phase I clinical trials for the treatment of multiple sclerosis (MS). However, the study had been discontinued. Development of Valategrast was
discontinued for the treatment of asthma after clarification of the regulatory framework for that class of compounds.
